| 4.33 -0.04 (-0.92%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.44 | 1-year : | 6.02 |
| Resists | First : | 4.65 | Second : | 5.15 |
| Pivot price | 4.32  |
|||
| Supports | First : | 3.84 | Second : | 3.2 |
| MAs | MA(5) : | 4.31  |
MA(20) : | 4.43 |
| MA(100) : | 4.65 |
MA(250) : | 4.99 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 55.2 |
D(3) : | 51 |
| RSI | RSI(14): 43.3 |
|||
| 52-week | High : | 6.75 | Low : | 3.84 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VNDA ] has closed below upper band by 49.5%. Bollinger Bands are 18.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.4 - 4.42 | 4.42 - 4.44 |
| Low: | 4.24 - 4.27 | 4.27 - 4.3 |
| Close: | 4.28 - 4.33 | 4.33 - 4.37 |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Mon, 07 Apr 2025
Vanda Pharmaceuticals: Financials Are Great, But Market Reaction Is Confusing (VNDA) - Seeking Alpha
Mon, 07 Apr 2025
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting - PR Newswire
Mon, 07 Apr 2025
FDA-Designated Precision Medicine Breakthrough: New Hope for Rare Genetic Disease Patients - Stock Titan
Thu, 03 Apr 2025
Class Action Update Vanda Pharmaceuticals Inc. (VNDA) & Stamps.com Inc. (STMP) - Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
Tue, 01 Apr 2025
Forecasting The Future: 5 Analyst Projections For Vanda Pharmaceuticals - Benzinga
Mon, 31 Mar 2025
Breakthrough Mental Health Drug Seeks FDA Approval for Bipolar and Schizophrenia - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 58 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 4.6 (%) |
| Held by Institutions | 76.3 (%) |
| Shares Short | 3,560 (K) |
| Shares Short P.Month | 3,720 (K) |
| EPS | -0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.23 |
| Profit Margin | -9.6 % |
| Operating Margin | -19.4 % |
| Return on Assets (ttm) | -4 % |
| Return on Equity (ttm) | -3.5 % |
| Qtrly Rev. Growth | 17.5 % |
| Gross Profit (p.s.) | 3.21 |
| Sales Per Share | 3.4 |
| EBITDA (p.s.) | -0.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -13.13 |
| PEG Ratio | 0 |
| Price to Book value | 0.46 |
| Price to Sales | 1.27 |
| Price to Cash Flow | -16.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|